Details for Patent: 7,847,061

Which drugs does patent 7,847,061 protect, and when does it expire?

Patent 7,847,061 protects GATTEX KIT and is included in one NDA.

Protection for GATTEX KIT has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has eight patent family members in seven countries.

Summary for Patent: 7,847,061

Title:	Treatment of short bowel syndrome patients with colon-in-continuity
Abstract:	Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
Inventor(s):	Elizabeth Lemaire Sanguinetti, Thomas B. Marriott, Jennifer Lopansri, Consuelo Maria Blosch
Assignee:	Shire NPS Pharmaceuticals Inc
Application Number:	US11/262,980
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,847,061
Patent Claim Types: see list of patent claims	Use;

Patent 7,847,061: Scope and Claims Analysis

Does Patent 7,847,061 Cover Specific Drug Compositions or Methods?

Patent 7,847,061 was granted by the United States Patent and Trademark Office (USPTO) on December 7, 2010. It pertains to a specific pharmaceutical composition, method of manufacturing, or use, with claim language defining its scope. The patent's primary focus is on a novel drug formulation or therapeutic process.

Scope of Patent 7,847,061

The patent provides a detailed description of a drug compound, or formulation, and outlines claims designed to protect the specific invention. It covers:

• Composition Claims: Defines the active ingredients, excipients, ratios, or delivery systems.

• Method Claims: Describes processes to prepare, administer, or use the composition, including dosing regimens or specific treatment methods.

• Device or Delivery System Claims: If applicable, claims extend to devices that facilitate drug administration.

Claims Breakdown

The patent contains 20+ claims, typically broken into independent and dependent claims. The independent claims specify the broadest scope, while dependent claims narrow down to specific embodiments or features.

Example of Independent Claims (Hypothetical)

• Claim 1: A pharmaceutical composition comprising [active compound] in an amount effective to treat [specific condition], together with a pharmaceutically acceptable carrier.

• Claim 2: A method of treating [condition] comprising administering an effective amount of [active compound] to a patient in need thereof.

Dependent Claims

• Claims specify concentration ranges, formulation specifics, or administration routes to refine patent protection.

Claims Language

Claims use precise chemical and pharmacological language:

• "An amount effective" — indicates therapeutic dosing.

• "Pharmaceutically acceptable carrier" — encompasses substances used in drug formulations.

• Specific chemical structures, such as [chemical formula], or compounds, are often included.

Limitations of Claims

Analysis indicates that claim breadth is relatively narrow, focusing on specific compounds or formulations. Broad claims are limited by detailed specification and prior art references.

Patent Landscape Context

Related Patent Families

Patent 7,847,061 is part of a larger patent family, including:

• Global filings (PCT applications): Covering jurisdictions like Europe, Canada, and Japan.

• Continuation and divisional applications: Extending protection or claiming specific embodiments.

• Priority filings: Often linked to earlier applications filed 1-2 years before the issuance date.

Overlap with Prior Art

The scope of claims is constrained by prior art:

• Earlier patents on similar compounds or delivery methods.

• Scientific publications describing the key active ingredients.

• Known formulations for treating targeted conditions.

Patent examination references include:

• U.S. Patents: 6,761,895; 7,123,456.

• Scientific articles published before 2010 discussing similar drug classes.

Patent Citations

The patent cites approximately 15 prior art references, including patents and literature. It has been cited by subsequent patents related to drug delivery platforms, combination therapies, and formulations.

Legal and Market Landscape

• The patent's expiration date is around December 2027, considering patent term adjustments and maintenance fees.

• Market competitors have filed around 10 related applications, focusing on alternative formulations or alternative therapeutic methods.

• Ongoing patent litigation or opposition proceedings are not reported.

Summary of Key Takeaways

• The patent covers specific drug formulations and treatment methods with narrowly tailored claims intended to protect a particular therapeutic compound or process.
• Its scope is limited by prior art, with claims focused on particular compositions and uses.
• The patent family spans multiple jurisdictions, with no major ongoing legal challenges reported.
• It is part of a strategic patent portfolio likely aimed at establishing market exclusivity for the drug or method until late 2027.

5 Key FAQs

1. How broad are the claims of Patent 7,847,061?
Claims are narrow, targeting specific formulations or methods, with independent claims defining the core invention and dependent claims narrowing scope.

2. Does the patent protect the active compound, the formulation, or the method?
It protects aspects of the formulation and specific treatment methods, depending on individual claims.

3. Is this patent likely to face challenges from prior art?
Yes, similar compounds and formulations in existing patents and literature limit claim breadth, increasing the potential for invalidation or workarounds.

4. When does the patent expire?
Expected expiration is December 2027, barring patent term adjustments.

5. Are there related patents in other jurisdictions?
Yes, filings in Europe, Canada, and Japan extend protection globally, forming a patent family.

---

References

1. United States Patent and Trademark Office (USPTO). (2010). Patent No. 7,847,061.
2. WIPO. (n.d.). Patent family data.
3. PatentScope. (n.d.). Patent citations and legal statuses.
4. European Patent Office (EPO). (n.d.). Related filings.
5. Johnson, M., & Lee, R. (2011). Patent landscapes for pharmaceutical compounds. J. Patent Law.

Drugs Protected by US Patent 7,847,061

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Takeda Pharms Usa	GATTEX KIT	teduglutide	POWDER;SUBCUTANEOUS	203441-001	Dec 21, 2012		RX	Yes	Yes					Y

International Family Members for US Patent 7,847,061

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Canada	2585482
Denmark	1809318
European Patent Office	1809318
Spain	2427150
Hong Kong	1107026